Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr;165(8):2736-48.
doi: 10.1111/j.1476-5381.2011.01714.x.

Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts

L N Axelsen  1 , W Keung, H D Pedersen, E Meier, D Riber, A L Kjølbye, J S Petersen, S D Proctor, N-H Holstein-Rathlou, G D Lopaschuk
Affiliations

Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts

L N Axelsen et al. Br J Pharmacol. 2012 Apr.

Abstract

Background and purpose: The prevalence of heart disease continues to rise, particularly in subjects with insulin resistance (IR), and improved therapies for these patients is an important challenge. In this study we evaluated cardiac function and energy metabolism in IR JCR:LA-cp rat hearts before and after treatment with an inotropic compound (glucagon), a glucagon-like peptide-1 (GLP-1) receptor agonist (ZP131) or a glucagon-GLP-1 dual-agonist (ZP2495).

Experimental approach: Hearts from IR and lean JCR:LA rats were isolated and perfused in the working heart mode for measurement of cardiac function and metabolism before and after addition of vehicle, glucagon, ZP131 or ZP2495. Subsequently, cardiac levels of nucleotides and short-chain CoA esters were measured by HPLC.

Key results: Hearts from IR rats showed decreased rates of glycolysis and glucose oxidation, plus increased palmitate oxidation rates, although cardiac function and energy state (measured by ATP/AMP ratios) was normal compared with control rats. Glucagon increased glucose oxidation and glycolytic rates in control and IR hearts, but the increase was not enough to avoid AMP and ADP accumulation in IR hearts. ZP131 had no significant metabolic or functional effects in either IR or control hearts. In contrast, ZP2495 increased glucose oxidation and glycolytic rates in IR hearts to a similar extent to that of glucagon but with no concomitant accumulation of AMP or ADP.

Conclusion and implications: Whereas glucagon compromised the energetic state of IR hearts, glucagon-GLP-1 dual-agonist ZP2495 appeared to preserve it. Therefore, a glucagon-GLP-1 dual-agonist may be beneficial compared with glucagon alone in the treatment of severe heart failure or cardiogenic shock in subjects with IR.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effects of vehicle, a GLP-1 receptor agonist (ZP131), glucagon and a glucagon-GLP-1 dual-agonist (ZP2495) on (A) heart rate in control JCR:LA rat hearts; (B) heart rate in insulin-resistant (IR) JCR:LA rat hearts; (C) cardiac output in control hearts; (D) cardiac output in IR hearts; (E) developed pressure in control hearts; (F) developed pressure in IR hearts; (G) cardiac power in control hearts; and (H) cardiac power in IR hearts. Values are presented as mean + SEM. *P < 0.05; **P < 0.01 compared with baseline by one-way anova for repeated measures followed by Dunnett's multiple comparison test.
Figure 2
Figure 2
Effects of vehicle, a GLP-1 receptor agonist (ZP131), glucagon and a glucagon-GLP-1 dual-agonist (ZP2495) on (A) glucose oxidation rates in control hearts; (B) glucose oxidation rates in IR hearts; (C) palmitate oxidation rates in control hearts; and (D) palmitate oxidation rates in IR hearts. Values are presented as mean + SEM. *P < 0.05; **P < 0.01 compared with baseline by one-way anova for repeated measures followed by Dunnett's multiple comparison test.
Figure 3
Figure 3
Effects of glucagon and a glucagon-GLP-1 dual-agonist (ZP2495) on (A) glucose oxidation rates in control hearts; (B) glucose oxidation rates in IR hearts; (C) glycolysis rates in control hearts; and (D) glycolysis rates in IR rat hearts. Values are presented as mean + SEM. *P < 0.05; **P < 0.01 compared with baseline by Student's paired t-test.
Figure 4
Figure 4
Short chain CoA concentrations in control and IR JCR:LA rat hearts after perfusion with vehicle, a GLP-1 receptor agonist (ZP131), glucagon and a glucagon-GLP-1 dual-agonist (ZP2495). (A) Malonyl CoA levels, (B) acetyl CoA levels, (C) free CoA levels and (D) succinyl CoA levels. Values are presented as mean + SEM. *P < 0.05; **P < 0.01 compared with vehicle by one-way anova for repeated measures followed by Dunnett's multiple comparison test. (For specific group sizes, see Figures 1 and 2).
Figure 5
Figure 5
Measured energy state in hearts from control and IR JCR:LA rats after perfusion with vehicle, a GLP-1 receptor agonist (ZP131), glucagon and a glucagon-GLP-1 dual-agonist (ZP2495). (A) AMP levels following a total of 65 min perfusion with increasing concentrations of vehicle, ZP131, glucagon or ZP2495. (B) ADP levels following perfusion with increasing concentrations of vehicle, ZP131, glucagon or ZP2495. (C) ATP levels following perfusion with increasing concentrations of vehicle, ZP131, glucagon or ZP2495. (D) ATP/AMP ratios following perfusion with increasing concentrations of vehicle, ZP131, glucagon or ZP2495. (E) ATP/ADP ratios following perfusion with increasing concentrations of vehicle, ZP131, glucagon or ZP2495. Values are presented as mean + SEM. *P < 0.05; **P < 0.01 compared with vehicle by one-way anova for repeated measures followed by Dunnett's multiple comparison test. (For specific group sizes, see Figure 1).
See this image and copyright information in PMC

References

    1. Ally A, Park G. Rapid determination of creatine, phosphocreatine, purine bases and nucleotides (ATP, ADP, AMP, GTP, GDP) in heart biopsies by gradient ion-pair reversed-phase liquid chromatography. J Chromatogr. 1992;575:19–27. - PubMed
    1. Atkinson LL, Kozak R, Kelly SE, Onay-Besikci A, Russell JC, Lopaschuk GD. Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats. Am J Physiol Endocrinol Metab. 2003;284:E923–E930. - PubMed
    1. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117:2340–2350. - PubMed
    1. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114–126. - PubMed
    1. Buse MG, Biggers JF, Drier C, Buse JF. The effect of epinephrine, glucagon, and the nutritional state on the oxidation of branched chain amino acids and pyruvate by isolated hearts and diaphragms of the rat. J Biol Chem. 1973;248:697–706. - PubMed

Publication types